ZURA Zura Bio Ltd
Price (delayed)
$3.63
Market cap
$243.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.24
Enterprise value
$55.52M
zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven
Highlights
The company's equity has surged by 157% QoQ and by 127% YoY
The quick ratio has surged by 121% year-on-year and by 104% since the previous quarter
Key stats
What are the main financial stats of ZURA
Market
Valuations
Earnings
Shares outstanding
67.21M
Market cap
$243.96M
Enterprise value
$55.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$34.82M
EBITDA
-$34.82M
Free cash flow
-$18.24M
Per share
Balance sheet
Liquidity
EPS
-$0.24
Free cash flow per share
-$0.24
Book value per share
$3.59
Revenue per share
$0
TBVPS
$2.53
Total assets
$189.5M
Total liabilities
$17.44M
Debt
$0
Equity
$156.52M
Working capital
$174.4M
Debt to equity
0
Current ratio
12.57
Quick ratio
12.5
Net debt/EBITDA
5.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23%
Return on equity
-32.9%
Return on invested capital
N/A
Return on capital employed
-20%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZURA stock price
How has the Zura Bio stock price performed over time
Intraday
-1.89%
1 week
1.11%
1 month
10.67%
1 year
-40.1%
YTD
-22.27%
QTD
3.71%
Financial performance
How have Zura Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.15M
Net income
-$34.82M
Gross margin
N/A
Net margin
N/A
ZURA's net income is up by 43% year-on-year and by 40% since the previous quarter
The operating income rose by 35% QoQ and by 31% YoY
Growth
What is Zura Bio's growth rate over time
Valuation
What is Zura Bio stock price valuation
P/E
N/A
P/B
1.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 100% year-on-year and by 83% since the previous quarter
The company's equity has surged by 157% QoQ and by 127% YoY
The price to book (P/B) is 62% less than the last 4 quarters average of 2.7
Efficiency
How efficient is Zura Bio business performance
Zura Bio's ROE has soared by 94% YoY and by 65% from the previous quarter
The return on assets has surged by 78% year-on-year and by 61% since the previous quarter
Dividends
What is ZURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZURA.
Financial health
How did Zura Bio financials performed over time
Zura Bio's current ratio has surged by 121% YoY and by 104% QoQ
The quick ratio has surged by 121% year-on-year and by 104% since the previous quarter
The debt is 100% smaller than the equity
The company's equity has surged by 157% QoQ and by 127% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.